nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—PTGS1—Thalidomide—leprosy	0.095	0.129	CbGbCtD
Carvedilol—CYP1A1—Thalidomide—leprosy	0.095	0.129	CbGbCtD
Carvedilol—PTGS1—Dapsone—leprosy	0.076	0.104	CbGbCtD
Carvedilol—CYP2E1—Thalidomide—leprosy	0.0734	0.1	CbGbCtD
Carvedilol—CYP2E1—Rifampicin—leprosy	0.0711	0.0969	CbGbCtD
Carvedilol—CYP2E1—Dapsone—leprosy	0.0587	0.08	CbGbCtD
Carvedilol—CYP1A2—Thalidomide—leprosy	0.0424	0.0578	CbGbCtD
Carvedilol—CYP1A2—Rifampicin—leprosy	0.0411	0.056	CbGbCtD
Carvedilol—CYP2C9—Thalidomide—leprosy	0.0382	0.0521	CbGbCtD
Carvedilol—CYP2C9—Rifampicin—leprosy	0.037	0.0505	CbGbCtD
Carvedilol—ABCB1—Rifampicin—leprosy	0.0359	0.049	CbGbCtD
Carvedilol—CYP2C9—Dapsone—leprosy	0.0306	0.0417	CbGbCtD
Carvedilol—CYP3A4—Rifampicin—leprosy	0.0215	0.0294	CbGbCtD
Carvedilol—CYP3A4—Dapsone—leprosy	0.0178	0.0242	CbGbCtD
Carvedilol—NPPB—blood vessel—leprosy	0.00779	0.081	CbGeAlD
Carvedilol—Periodontitis—Thalidomide—leprosy	0.00766	0.0571	CcSEcCtD
Carvedilol—GJA1—skin epidermis—leprosy	0.00675	0.0702	CbGeAlD
Carvedilol—HIF1A—nerve—leprosy	0.00593	0.0617	CbGeAlD
Carvedilol—SELE—blood vessel—leprosy	0.00526	0.0547	CbGeAlD
Carvedilol—VCAM1—blood vessel—leprosy	0.00484	0.0504	CbGeAlD
Carvedilol—HIF1A—blood vessel—leprosy	0.00466	0.0484	CbGeAlD
Carvedilol—GJA1—blood vessel—leprosy	0.00452	0.047	CbGeAlD
Carvedilol—Albuminuria—Dapsone—leprosy	0.00291	0.0217	CcSEcCtD
Carvedilol—Rales—Thalidomide—leprosy	0.00271	0.0202	CcSEcCtD
Carvedilol—VCAM1—eye—leprosy	0.00258	0.0268	CbGeAlD
Carvedilol—HIF1A—eye—leprosy	0.00248	0.0258	CbGeAlD
Carvedilol—SELE—skin of body—leprosy	0.00244	0.0253	CbGeAlD
Carvedilol—GJA1—eye—leprosy	0.0024	0.025	CbGeAlD
Carvedilol—Peripheral vascular disorder—Thalidomide—leprosy	0.00227	0.0169	CcSEcCtD
Carvedilol—Sinus bradycardia—Thalidomide—leprosy	0.00227	0.0169	CcSEcCtD
Carvedilol—NDUFC2—Respiratory electron transport—SDHD—leprosy	0.00224	0.0621	CbGpPWpGaD
Carvedilol—NPPB—nervous system—leprosy	0.00223	0.0232	CbGeAlD
Carvedilol—HIF1A—skin of body—leprosy	0.00216	0.0224	CbGeAlD
Carvedilol—NDUFC2—eye—leprosy	0.00209	0.0218	CbGeAlD
Carvedilol—GJA1—skin of body—leprosy	0.00209	0.0218	CbGeAlD
Carvedilol—VCAM1—Beta2 integrin cell surface interactions—CD40LG—leprosy	0.00195	0.0541	CbGpPWpGaD
Carvedilol—NDUFC2—Electron Transport Chain—SDHD—leprosy	0.00194	0.0537	CbGpPWpGaD
Carvedilol—NDUFC2—Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.—SDHD—leprosy	0.00189	0.0525	CbGpPWpGaD
Carvedilol—SELE—tendon—leprosy	0.00185	0.0193	CbGeAlD
Carvedilol—Psoriasis—Thalidomide—leprosy	0.00177	0.0132	CcSEcCtD
Carvedilol—VCAM1—tendon—leprosy	0.00171	0.0177	CbGeAlD
Carvedilol—ADRA2A—peripheral nervous system—leprosy	0.00166	0.0173	CbGeAlD
Carvedilol—HIF1A—tendon—leprosy	0.00164	0.0171	CbGeAlD
Carvedilol—CYP1A1—skin epidermis—leprosy	0.00163	0.017	CbGeAlD
Carvedilol—Neuralgia—Thalidomide—leprosy	0.0016	0.0119	CcSEcCtD
Carvedilol—GJA1—tendon—leprosy	0.00159	0.0166	CbGeAlD
Carvedilol—Lung disorder—Thalidomide—leprosy	0.00157	0.0117	CcSEcCtD
Carvedilol—Interstitial lung disease—Thalidomide—leprosy	0.00157	0.0117	CcSEcCtD
Carvedilol—Psychotic disorder—Dapsone—leprosy	0.00154	0.0115	CcSEcCtD
Carvedilol—SELE—testis—leprosy	0.00154	0.016	CbGeAlD
Carvedilol—SELE—nervous system—leprosy	0.00151	0.0157	CbGeAlD
Carvedilol—Albuminuria—Thalidomide—leprosy	0.00149	0.0111	CcSEcCtD
Carvedilol—NDUFC2—The citric acid (TCA) cycle and respiratory electron transport—SDHD—leprosy	0.00146	0.0404	CbGpPWpGaD
Carvedilol—Hyperaesthesia—Thalidomide—leprosy	0.00142	0.0106	CcSEcCtD
Carvedilol—VCAM1—testis—leprosy	0.00141	0.0147	CbGeAlD
Carvedilol—Nasopharyngitis—Dapsone—leprosy	0.00141	0.0105	CcSEcCtD
Carvedilol—VCAM1—nervous system—leprosy	0.00139	0.0144	CbGeAlD
Carvedilol—NDUFC2—tendon—leprosy	0.00139	0.0144	CbGeAlD
Carvedilol—Myocardial ischaemia—Thalidomide—leprosy	0.00138	0.0103	CcSEcCtD
Carvedilol—Influenza—Dapsone—leprosy	0.00136	0.0102	CcSEcCtD
Carvedilol—HIF1A—testis—leprosy	0.00136	0.0141	CbGeAlD
Carvedilol—HIF1A—nervous system—leprosy	0.00133	0.0139	CbGeAlD
Carvedilol—GJA1—testis—leprosy	0.00132	0.0137	CbGeAlD
Carvedilol—GJA1—nervous system—leprosy	0.00129	0.0135	CbGeAlD
Carvedilol—VEGFA—tendon—leprosy	0.00126	0.0131	CbGeAlD
Carvedilol—Accidental injury—Thalidomide—leprosy	0.00126	0.00937	CcSEcCtD
Carvedilol—Photosensitivity reaction—Dapsone—leprosy	0.00124	0.00927	CcSEcCtD
Carvedilol—Viral infection—Thalidomide—leprosy	0.00123	0.00918	CcSEcCtD
Carvedilol—Hyperbilirubinaemia—Thalidomide—leprosy	0.00122	0.00911	CcSEcCtD
Carvedilol—Thinking abnormal—Thalidomide—leprosy	0.00121	0.00905	CcSEcCtD
Carvedilol—Hyperuricaemia—Thalidomide—leprosy	0.0012	0.00893	CcSEcCtD
Carvedilol—Hypercholesterolaemia—Thalidomide—leprosy	0.00117	0.00876	CcSEcCtD
Carvedilol—Creatinine increased—Thalidomide—leprosy	0.00117	0.00871	CcSEcCtD
Carvedilol—Hearing impaired—Thalidomide—leprosy	0.00117	0.00871	CcSEcCtD
Carvedilol—NDUFC2—testis—leprosy	0.00115	0.0119	CbGeAlD
Carvedilol—Atrioventricular block—Thalidomide—leprosy	0.00115	0.00854	CcSEcCtD
Carvedilol—Sinusitis—Dapsone—leprosy	0.00114	0.0085	CcSEcCtD
Carvedilol—Blood uric acid increased—Thalidomide—leprosy	0.00113	0.00844	CcSEcCtD
Carvedilol—NDUFC2—nervous system—leprosy	0.00113	0.0117	CbGeAlD
Carvedilol—Phosphatase alkaline increased—Thalidomide—leprosy	0.00111	0.00829	CcSEcCtD
Carvedilol—Hyperkalaemia—Thalidomide—leprosy	0.00109	0.00814	CcSEcCtD
Carvedilol—Pharyngitis—Dapsone—leprosy	0.00108	0.00807	CcSEcCtD
Carvedilol—Blood urea increased—Thalidomide—leprosy	0.00105	0.00782	CcSEcCtD
Carvedilol—Aplastic anaemia—Thalidomide—leprosy	0.00104	0.00778	CcSEcCtD
Carvedilol—VEGFA—testis—leprosy	0.00104	0.0108	CbGeAlD
Carvedilol—Cramps of lower extremities—Thalidomide—leprosy	0.00102	0.00761	CcSEcCtD
Carvedilol—Tinnitus—Dapsone—leprosy	0.00102	0.00758	CcSEcCtD
Carvedilol—Rash maculo-papular—Thalidomide—leprosy	0.00101	0.00753	CcSEcCtD
Carvedilol—Lightheadedness—Thalidomide—leprosy	0.000994	0.00742	CcSEcCtD
Carvedilol—Pulmonary oedema—Thalidomide—leprosy	0.000989	0.00738	CcSEcCtD
Carvedilol—SELE—ATF-2 transcription factor network—IFNG—leprosy	0.000986	0.0273	CbGpPWpGaD
Carvedilol—NPPB—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000985	0.0273	CbGpPWpGaD
Carvedilol—Mental disability—Thalidomide—leprosy	0.000964	0.00719	CcSEcCtD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD40LG—leprosy	0.000964	0.0267	CbGpPWpGaD
Carvedilol—PTGS1—blood vessel—leprosy	0.000959	0.00998	CbGeAlD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD8A—leprosy	0.000953	0.0264	CbGpPWpGaD
Carvedilol—Diabetes mellitus—Thalidomide—leprosy	0.000927	0.00692	CcSEcCtD
Carvedilol—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000927	0.00692	CcSEcCtD
Carvedilol—VCAM1—Cellular roles of Anthrax toxin—TNF—leprosy	0.000926	0.0257	CbGpPWpGaD
Carvedilol—Vascular purpura—Thalidomide—leprosy	0.000902	0.00673	CcSEcCtD
Carvedilol—Vision blurred—Dapsone—leprosy	0.000894	0.00667	CcSEcCtD
Carvedilol—GJA1—AP-1 transcription factor network—IL10—leprosy	0.000886	0.0246	CbGpPWpGaD
Carvedilol—Injury—Thalidomide—leprosy	0.000877	0.00655	CcSEcCtD
Carvedilol—Renal failure acute—Thalidomide—leprosy	0.000874	0.00652	CcSEcCtD
Carvedilol—Libido decreased—Thalidomide—leprosy	0.00087	0.00649	CcSEcCtD
Carvedilol—Amnesia—Thalidomide—leprosy	0.000858	0.0064	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Thalidomide—leprosy	0.000855	0.00638	CcSEcCtD
Carvedilol—HIF1A—AP-1 transcription factor network—IL10—leprosy	0.000854	0.0237	CbGpPWpGaD
Carvedilol—Vertigo—Dapsone—leprosy	0.000852	0.00636	CcSEcCtD
Carvedilol—Atrial fibrillation—Thalidomide—leprosy	0.000851	0.00635	CcSEcCtD
Carvedilol—Purpura—Thalidomide—leprosy	0.000837	0.00624	CcSEcCtD
Carvedilol—Arthritis—Thalidomide—leprosy	0.00083	0.00619	CcSEcCtD
Carvedilol—Cough—Dapsone—leprosy	0.000828	0.00618	CcSEcCtD
Carvedilol—Cardiac failure—Thalidomide—leprosy	0.000826	0.00616	CcSEcCtD
Carvedilol—Hypoglycaemia—Thalidomide—leprosy	0.000826	0.00616	CcSEcCtD
Carvedilol—Cerebrovascular accident—Thalidomide—leprosy	0.000823	0.00614	CcSEcCtD
Carvedilol—Hyponatraemia—Thalidomide—leprosy	0.00081	0.00604	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000807	0.00602	CcSEcCtD
Carvedilol—Pain in extremity—Thalidomide—leprosy	0.000807	0.00602	CcSEcCtD
Carvedilol—Disturbance in sexual arousal—Thalidomide—leprosy	0.0008	0.00597	CcSEcCtD
Carvedilol—Affect lability—Thalidomide—leprosy	0.000794	0.00592	CcSEcCtD
Carvedilol—Migraine—Thalidomide—leprosy	0.000794	0.00592	CcSEcCtD
Carvedilol—Psychotic disorder—Thalidomide—leprosy	0.000788	0.00588	CcSEcCtD
Carvedilol—VCAM1—Interferon gamma signaling—HLA-DRB1—leprosy	0.000785	0.0218	CbGpPWpGaD
Carvedilol—Cardiac arrest—Thalidomide—leprosy	0.000767	0.00572	CcSEcCtD
Carvedilol—Mood swings—Thalidomide—leprosy	0.000764	0.0057	CcSEcCtD
Carvedilol—SELE—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.000758	0.021	CbGpPWpGaD
Carvedilol—Tachycardia—Dapsone—leprosy	0.000756	0.00564	CcSEcCtD
Carvedilol—Blood creatinine increased—Thalidomide—leprosy	0.000756	0.00564	CcSEcCtD
Carvedilol—Dehydration—Thalidomide—leprosy	0.00075	0.00559	CcSEcCtD
Carvedilol—Orthostatic hypotension—Thalidomide—leprosy	0.000737	0.00549	CcSEcCtD
Carvedilol—Hypokalaemia—Thalidomide—leprosy	0.000734	0.00548	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000726	0.00542	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000726	0.00542	CcSEcCtD
Carvedilol—Cramp muscle—Thalidomide—leprosy	0.000726	0.00542	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Thalidomide—leprosy	0.000711	0.00531	CcSEcCtD
Carvedilol—Insomnia—Dapsone—leprosy	0.0007	0.00522	CcSEcCtD
Carvedilol—Influenza—Thalidomide—leprosy	0.000697	0.0052	CcSEcCtD
Carvedilol—Bronchospasm—Thalidomide—leprosy	0.000686	0.00511	CcSEcCtD
Carvedilol—ADRA1B—nervous system—leprosy	0.000682	0.0071	CbGeAlD
Carvedilol—Angina pectoris—Thalidomide—leprosy	0.000679	0.00506	CcSEcCtD
Carvedilol—SELE—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000673	0.0187	CbGpPWpGaD
Carvedilol—Bronchitis—Thalidomide—leprosy	0.00067	0.005	CcSEcCtD
Carvedilol—ADRA1D—nervous system—leprosy	0.000668	0.00694	CbGeAlD
Carvedilol—HIF1A—Notch-mediated HES/HEY network—CD4—leprosy	0.000667	0.0185	CbGpPWpGaD
Carvedilol—Pancytopenia—Thalidomide—leprosy	0.000662	0.00494	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Thalidomide—leprosy	0.000648	0.00483	CcSEcCtD
Carvedilol—Pollakiuria—Thalidomide—leprosy	0.000644	0.0048	CcSEcCtD
Carvedilol—Erectile dysfunction—Thalidomide—leprosy	0.000642	0.00479	CcSEcCtD
Carvedilol—Photosensitivity reaction—Thalidomide—leprosy	0.000636	0.00475	CcSEcCtD
Carvedilol—Weight increased—Thalidomide—leprosy	0.000634	0.00473	CcSEcCtD
Carvedilol—Gastrointestinal pain—Dapsone—leprosy	0.000633	0.00472	CcSEcCtD
Carvedilol—Weight decreased—Thalidomide—leprosy	0.000631	0.0047	CcSEcCtD
Carvedilol—Hyperglycaemia—Thalidomide—leprosy	0.000629	0.00469	CcSEcCtD
Carvedilol—Pneumonia—Thalidomide—leprosy	0.000625	0.00466	CcSEcCtD
Carvedilol—Depression—Thalidomide—leprosy	0.00062	0.00462	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000616	0.0046	CcSEcCtD
Carvedilol—Acute coronary syndrome—Thalidomide—leprosy	0.000613	0.00457	CcSEcCtD
Carvedilol—Body temperature increased—Dapsone—leprosy	0.000612	0.00457	CcSEcCtD
Carvedilol—Abdominal pain—Dapsone—leprosy	0.000612	0.00457	CcSEcCtD
Carvedilol—Renal failure—Thalidomide—leprosy	0.000611	0.00456	CcSEcCtD
Carvedilol—Myocardial infarction—Thalidomide—leprosy	0.000609	0.00454	CcSEcCtD
Carvedilol—Haematuria—Thalidomide—leprosy	0.000593	0.00442	CcSEcCtD
Carvedilol—VEGFA—Hypertrophy Model—IFNG—leprosy	0.000591	0.0164	CbGpPWpGaD
Carvedilol—Sinusitis—Thalidomide—leprosy	0.000583	0.00435	CcSEcCtD
Carvedilol—VCAM1—Interferon gamma signaling—IFNG—leprosy	0.000573	0.0159	CbGpPWpGaD
Carvedilol—Bradycardia—Thalidomide—leprosy	0.000568	0.00424	CcSEcCtD
Carvedilol—ABCB1—blood vessel—leprosy	0.000567	0.0059	CbGeAlD
Carvedilol—Rhinitis—Thalidomide—leprosy	0.000559	0.00417	CcSEcCtD
Carvedilol—Hypoaesthesia—Thalidomide—leprosy	0.000555	0.00414	CcSEcCtD
Carvedilol—Pharyngitis—Thalidomide—leprosy	0.000554	0.00413	CcSEcCtD
Carvedilol—Urinary tract disorder—Thalidomide—leprosy	0.000551	0.00411	CcSEcCtD
Carvedilol—Oedema peripheral—Thalidomide—leprosy	0.00055	0.0041	CcSEcCtD
Carvedilol—Urethral disorder—Thalidomide—leprosy	0.000547	0.00408	CcSEcCtD
Carvedilol—Visual impairment—Thalidomide—leprosy	0.000538	0.00401	CcSEcCtD
Carvedilol—Erythema multiforme—Thalidomide—leprosy	0.000528	0.00394	CcSEcCtD
Carvedilol—GJA1—AP-1 transcription factor network—IFNG—leprosy	0.000521	0.0144	CbGpPWpGaD
Carvedilol—Tinnitus—Thalidomide—leprosy	0.00052	0.00388	CcSEcCtD
Carvedilol—Angiopathy—Thalidomide—leprosy	0.000506	0.00378	CcSEcCtD
Carvedilol—CYP1A1—skin of body—leprosy	0.000506	0.00526	CbGeAlD
Carvedilol—Immune system disorder—Thalidomide—leprosy	0.000504	0.00376	CcSEcCtD
Carvedilol—Mediastinal disorder—Thalidomide—leprosy	0.000503	0.00375	CcSEcCtD
Carvedilol—HIF1A—AP-1 transcription factor network—IFNG—leprosy	0.000502	0.0139	CbGpPWpGaD
Carvedilol—Alopecia—Thalidomide—leprosy	0.000493	0.00368	CcSEcCtD
Carvedilol—Vomiting—Dapsone—leprosy	0.000492	0.00367	CcSEcCtD
Carvedilol—Malnutrition—Thalidomide—leprosy	0.000486	0.00362	CcSEcCtD
Carvedilol—Headache—Dapsone—leprosy	0.000485	0.00362	CcSEcCtD
Carvedilol—ADRB1—nervous system—leprosy	0.000485	0.00504	CbGeAlD
Carvedilol—Flatulence—Thalidomide—leprosy	0.000479	0.00357	CcSEcCtD
Carvedilol—Tension—Thalidomide—leprosy	0.000477	0.00356	CcSEcCtD
Carvedilol—Nervousness—Thalidomide—leprosy	0.000472	0.00352	CcSEcCtD
Carvedilol—Back pain—Thalidomide—leprosy	0.00047	0.0035	CcSEcCtD
Carvedilol—Muscle spasms—Thalidomide—leprosy	0.000467	0.00348	CcSEcCtD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL10—leprosy	0.000467	0.0129	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—IL2—leprosy	0.000463	0.0128	CbGpPWpGaD
Carvedilol—Nausea—Dapsone—leprosy	0.00046	0.00343	CcSEcCtD
Carvedilol—Vision blurred—Thalidomide—leprosy	0.000458	0.00341	CcSEcCtD
Carvedilol—Ill-defined disorder—Thalidomide—leprosy	0.000451	0.00336	CcSEcCtD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL10—leprosy	0.00045	0.0125	CbGpPWpGaD
Carvedilol—ADRA2C—tendon—leprosy	0.00045	0.00468	CbGeAlD
Carvedilol—Anaemia—Thalidomide—leprosy	0.000449	0.00335	CcSEcCtD
Carvedilol—SELE—TNF alpha Signaling Pathway—TNF—leprosy	0.000447	0.0124	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—IL2—leprosy	0.000446	0.0124	CbGpPWpGaD
Carvedilol—PTGS1—skin of body—leprosy	0.000444	0.00462	CbGeAlD
Carvedilol—Angioedema—Thalidomide—leprosy	0.000444	0.00331	CcSEcCtD
Carvedilol—Malaise—Thalidomide—leprosy	0.000438	0.00327	CcSEcCtD
Carvedilol—Vertigo—Thalidomide—leprosy	0.000436	0.00326	CcSEcCtD
Carvedilol—Syncope—Thalidomide—leprosy	0.000436	0.00325	CcSEcCtD
Carvedilol—Leukopenia—Thalidomide—leprosy	0.000435	0.00324	CcSEcCtD
Carvedilol—Palpitations—Thalidomide—leprosy	0.000429	0.0032	CcSEcCtD
Carvedilol—Loss of consciousness—Thalidomide—leprosy	0.000427	0.00318	CcSEcCtD
Carvedilol—Cough—Thalidomide—leprosy	0.000424	0.00316	CcSEcCtD
Carvedilol—Convulsion—Thalidomide—leprosy	0.000421	0.00314	CcSEcCtD
Carvedilol—Hypertension—Thalidomide—leprosy	0.000419	0.00313	CcSEcCtD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000415	0.0115	CbGpPWpGaD
Carvedilol—Arthralgia—Thalidomide—leprosy	0.000413	0.00308	CcSEcCtD
Carvedilol—Myalgia—Thalidomide—leprosy	0.000413	0.00308	CcSEcCtD
Carvedilol—Chest pain—Thalidomide—leprosy	0.000413	0.00308	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000411	0.00306	CcSEcCtD
Carvedilol—Discomfort—Thalidomide—leprosy	0.000409	0.00305	CcSEcCtD
Carvedilol—Dry mouth—Thalidomide—leprosy	0.000404	0.00302	CcSEcCtD
Carvedilol—Confusional state—Thalidomide—leprosy	0.0004	0.00298	CcSEcCtD
Carvedilol—Oedema—Thalidomide—leprosy	0.000396	0.00296	CcSEcCtD
Carvedilol—Infection—Thalidomide—leprosy	0.000394	0.00294	CcSEcCtD
Carvedilol—Shock—Thalidomide—leprosy	0.00039	0.00291	CcSEcCtD
Carvedilol—Thrombocytopenia—Thalidomide—leprosy	0.000388	0.0029	CcSEcCtD
Carvedilol—Tachycardia—Thalidomide—leprosy	0.000387	0.00289	CcSEcCtD
Carvedilol—Skin disorder—Thalidomide—leprosy	0.000385	0.00287	CcSEcCtD
Carvedilol—VCAM1—Interferon Signaling—HLA-DRB1—leprosy	0.000383	0.0106	CbGpPWpGaD
Carvedilol—ADRA1A—nervous system—leprosy	0.000383	0.00399	CbGeAlD
Carvedilol—Hyperhidrosis—Thalidomide—leprosy	0.000383	0.00286	CcSEcCtD
Carvedilol—Anorexia—Thalidomide—leprosy	0.000378	0.00282	CcSEcCtD
Carvedilol—KCNH2—testis—leprosy	0.000377	0.00392	CbGeAlD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—NOD2—leprosy	0.000376	0.0104	CbGpPWpGaD
Carvedilol—ADRA2C—testis—leprosy	0.000372	0.00387	CbGeAlD
Carvedilol—GJA1—Corticotropin-releasing hormone—IL2—leprosy	0.000372	0.0103	CbGpPWpGaD
Carvedilol—Hypotension—Thalidomide—leprosy	0.00037	0.00276	CcSEcCtD
Carvedilol—KCNH2—nervous system—leprosy	0.00037	0.00385	CbGeAlD
Carvedilol—ADRA2C—nervous system—leprosy	0.000365	0.0038	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Thalidomide—leprosy	0.000361	0.00269	CcSEcCtD
Carvedilol—ADRA2A—tendon—leprosy	0.000359	0.00373	CbGeAlD
Carvedilol—Insomnia—Thalidomide—leprosy	0.000359	0.00267	CcSEcCtD
Carvedilol—Paraesthesia—Thalidomide—leprosy	0.000356	0.00266	CcSEcCtD
Carvedilol—Dyspnoea—Thalidomide—leprosy	0.000353	0.00264	CcSEcCtD
Carvedilol—Somnolence—Thalidomide—leprosy	0.000352	0.00263	CcSEcCtD
Carvedilol—CYP2E1—tendon—leprosy	0.000351	0.00365	CbGeAlD
Carvedilol—Dyspepsia—Thalidomide—leprosy	0.000349	0.0026	CcSEcCtD
Carvedilol—Decreased appetite—Thalidomide—leprosy	0.000345	0.00257	CcSEcCtD
Carvedilol—GJA1—Spinal Cord Injury—IFNG—leprosy	0.000343	0.00952	CbGpPWpGaD
Carvedilol—Gastrointestinal disorder—Thalidomide—leprosy	0.000342	0.00255	CcSEcCtD
Carvedilol—Fatigue—Thalidomide—leprosy	0.000342	0.00255	CcSEcCtD
Carvedilol—Constipation—Thalidomide—leprosy	0.000339	0.00253	CcSEcCtD
Carvedilol—Pain—Thalidomide—leprosy	0.000339	0.00253	CcSEcCtD
Carvedilol—PTGS1—tendon—leprosy	0.000338	0.00352	CbGeAlD
Carvedilol—VEGFA—Allograft Rejection—IL10—leprosy	0.000335	0.00928	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—CD40LG—leprosy	0.000335	0.00928	CbGpPWpGaD
Carvedilol—Feeling abnormal—Thalidomide—leprosy	0.000327	0.00244	CcSEcCtD
Carvedilol—Gastrointestinal pain—Thalidomide—leprosy	0.000324	0.00242	CcSEcCtD
Carvedilol—Urticaria—Thalidomide—leprosy	0.000315	0.00235	CcSEcCtD
Carvedilol—Abdominal pain—Thalidomide—leprosy	0.000313	0.00234	CcSEcCtD
Carvedilol—Body temperature increased—Thalidomide—leprosy	0.000313	0.00234	CcSEcCtD
Carvedilol—CYP1A1—nervous system—leprosy	0.000313	0.00325	CbGeAlD
Carvedilol—VCAM1—Adaptive Immune System—PARK2—leprosy	0.000307	0.0085	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—IL2—leprosy	0.000305	0.00846	CbGpPWpGaD
Carvedilol—ADRA2A—testis—leprosy	0.000297	0.00309	CbGeAlD
Carvedilol—Hypersensitivity—Thalidomide—leprosy	0.000292	0.00218	CcSEcCtD
Carvedilol—ADRA2A—nervous system—leprosy	0.000292	0.00303	CbGeAlD
Carvedilol—CYP2E1—testis—leprosy	0.000291	0.00302	CbGeAlD
Carvedilol—CYP2E1—nervous system—leprosy	0.000285	0.00297	CbGeAlD
Carvedilol—Asthenia—Thalidomide—leprosy	0.000284	0.00212	CcSEcCtD
Carvedilol—Pruritus—Thalidomide—leprosy	0.00028	0.00209	CcSEcCtD
Carvedilol—VCAM1—Interferon Signaling—IFNG—leprosy	0.00028	0.00777	CbGpPWpGaD
Carvedilol—PTGS1—testis—leprosy	0.00028	0.00291	CbGeAlD
Carvedilol—PTGS1—nervous system—leprosy	0.000275	0.00286	CbGeAlD
Carvedilol—Diarrhoea—Thalidomide—leprosy	0.000271	0.00202	CcSEcCtD
Carvedilol—VEGFA—Allograft Rejection—HLA-DRB1—leprosy	0.000269	0.00747	CbGpPWpGaD
Carvedilol—Dizziness—Thalidomide—leprosy	0.000262	0.00196	CcSEcCtD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000256	0.0071	CbGpPWpGaD
Carvedilol—Vomiting—Thalidomide—leprosy	0.000252	0.00188	CcSEcCtD
Carvedilol—VEGFA—SHP2 signaling—IFNG—leprosy	0.000252	0.00699	CbGpPWpGaD
Carvedilol—Rash—Thalidomide—leprosy	0.00025	0.00186	CcSEcCtD
Carvedilol—Dermatitis—Thalidomide—leprosy	0.00025	0.00186	CcSEcCtD
Carvedilol—Headache—Thalidomide—leprosy	0.000248	0.00185	CcSEcCtD
Carvedilol—Nausea—Thalidomide—leprosy	0.000235	0.00176	CcSEcCtD
Carvedilol—CYP2D6—testis—leprosy	0.00023	0.00239	CbGeAlD
Carvedilol—CYP3A4—nervous system—leprosy	0.000229	0.00239	CbGeAlD
Carvedilol—CYP2D6—nervous system—leprosy	0.000226	0.00235	CbGeAlD
Carvedilol—VEGFA—SHP2 signaling—IL2—leprosy	0.000224	0.00621	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—RIPK2—leprosy	0.000223	0.0062	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—TNF—leprosy	0.000222	0.00616	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—SDHD—leprosy	0.00022	0.0061	CbGpPWpGaD
Carvedilol—PTGS1—Overview of nanoparticle effects—TNF—leprosy	0.000219	0.00607	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—IFNG—leprosy	0.000212	0.00588	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CYLD—leprosy	0.00021	0.00583	CbGpPWpGaD
Carvedilol—HIF1A—Adipogenesis—TNF—leprosy	0.000198	0.0055	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IFNG—leprosy	0.000197	0.00546	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000196	0.00545	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL10—leprosy	0.000194	0.00539	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IFNG—leprosy	0.000187	0.00519	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—PARK2—leprosy	0.000186	0.00516	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—TNF—leprosy	0.000178	0.00493	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL10—leprosy	0.000176	0.00488	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IL2—leprosy	0.000175	0.00485	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—TNF—leprosy	0.000171	0.00475	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD40LG—leprosy	0.000171	0.00475	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD8A—leprosy	0.000169	0.0047	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IL2—leprosy	0.000166	0.00461	CbGpPWpGaD
Carvedilol—ABCB1—testis—leprosy	0.000166	0.00172	CbGeAlD
Carvedilol—ABCB1—nervous system—leprosy	0.000162	0.00169	CbGeAlD
Carvedilol—SELE—Hemostasis—IL2—leprosy	0.000157	0.00435	CbGpPWpGaD
Carvedilol—HIF1A—Disease—SLC11A1—leprosy	0.000152	0.00422	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-DRB1—leprosy	0.000138	0.00382	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—TNF—leprosy	0.000137	0.0038	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—RIPK2—leprosy	0.000136	0.00376	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—TLR2—leprosy	0.000136	0.00376	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—TNF—leprosy	0.000127	0.00353	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—NOD2—leprosy	0.000123	0.00341	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000117	0.00326	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000104	0.00289	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD40LG—leprosy	0.000104	0.00288	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL10—leprosy	0.000103	0.00287	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CD40LG—leprosy	0.000103	0.00287	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD8A—leprosy	0.000103	0.00285	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—IFNG—leprosy	9.92e-05	0.00275	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD4—leprosy	9.73e-05	0.0027	CbGpPWpGaD
Carvedilol—XDH—Metabolism—SDHD—leprosy	8.58e-05	0.00238	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-DRB1—leprosy	8.36e-05	0.00232	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	8.33e-05	0.00231	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—RIPK2—leprosy	7.76e-05	0.00215	CbGpPWpGaD
Carvedilol—VEGFA—Platelet activation, signaling and aggregation—IL2—leprosy	7.68e-05	0.00213	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	7.6e-05	0.00211	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—leprosy	7.6e-05	0.00211	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	7.49e-05	0.00208	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—TNF—leprosy	7.39e-05	0.00205	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—TNF—leprosy	6.7e-05	0.00186	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	6.65e-05	0.00185	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—TNF—leprosy	6.42e-05	0.00178	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.29e-05	0.00174	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IFNG—leprosy	6.11e-05	0.00169	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IFNG—leprosy	6.08e-05	0.00169	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD4—leprosy	5.9e-05	0.00164	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL2—leprosy	5.43e-05	0.00151	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL2—leprosy	5.41e-05	0.0015	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	4.85e-05	0.00134	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	4.85e-05	0.00134	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CD4—leprosy	4.83e-05	0.00134	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—IL2—leprosy	4.53e-05	0.00126	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—IL2—leprosy	4.23e-05	0.00117	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—SDHD—leprosy	4.03e-05	0.00112	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—SDHD—leprosy	4.02e-05	0.00111	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—IL2—leprosy	3.96e-05	0.0011	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—TNF—leprosy	3.94e-05	0.00109	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	3.63e-05	0.00101	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—IL2—leprosy	3.43e-05	0.000952	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RIPK2—leprosy	3.36e-05	0.000931	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RIPK2—leprosy	3.35e-05	0.000929	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—SDHD—leprosy	3.27e-05	0.000907	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL2—leprosy	3.11e-05	0.000862	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—SDHD—leprosy	3e-05	0.000833	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—leprosy	2.94e-05	0.000815	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—SDHD—leprosy	2.83e-05	0.000785	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—IL2—leprosy	2.51e-05	0.000695	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—IL2—leprosy	2.33e-05	0.000647	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL2—leprosy	2.28e-05	0.000631	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SDHD—leprosy	2.26e-05	0.000627	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RIPK2—leprosy	2.19e-05	0.000607	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—IL2—leprosy	2.18e-05	0.000604	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SDHD—leprosy	2.13e-05	0.000591	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SDHD—leprosy	2.11e-05	0.000586	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RIPK2—leprosy	1.99e-05	0.000553	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RIPK2—leprosy	1.97e-05	0.000548	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RIPK2—leprosy	1.95e-05	0.000541	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1.94e-05	0.000539	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RIPK2—leprosy	1.84e-05	0.000512	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RIPK2—leprosy	1.82e-05	0.000504	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SDHD—leprosy	1.81e-05	0.000501	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—IL2—leprosy	1.77e-05	0.000491	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—IL2—leprosy	1.63e-05	0.000453	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RIPK2—leprosy	1.61e-05	0.000447	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RIPK2—leprosy	1.5e-05	0.000416	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2—leprosy	1.49e-05	0.000413	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2—leprosy	1.48e-05	0.000411	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2—leprosy	1.47e-05	0.000409	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2—leprosy	1.46e-05	0.000404	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SDHD—leprosy	1.39e-05	0.000386	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2—leprosy	1.38e-05	0.000382	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2—leprosy	1.36e-05	0.000376	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2—leprosy	1.35e-05	0.000375	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2—leprosy	1.34e-05	0.000373	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2—leprosy	1.34e-05	0.000372	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2—leprosy	1.34e-05	0.000371	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2—leprosy	1.32e-05	0.000367	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2—leprosy	1.25e-05	0.000347	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2—leprosy	1.23e-05	0.000341	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2—leprosy	1.2e-05	0.000334	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—leprosy	1.12e-05	0.00031	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—leprosy	1.09e-05	0.000303	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—leprosy	1.02e-05	0.000282	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—leprosy	8.76e-06	0.000243	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—leprosy	7.98e-06	0.000221	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—leprosy	7.91e-06	0.000219	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—leprosy	7.81e-06	0.000217	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—leprosy	7.39e-06	0.000205	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—leprosy	7.27e-06	0.000202	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—leprosy	6.46e-06	0.000179	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—leprosy	6e-06	0.000166	CbGpPWpGaD
